Physician profile
Kelsey Moon
NPI 1962852186
$8,480.15
in general payments reported to CMS, 2019-2025
50 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $1,647 · 2021: $2,171 · 2022: $1,678 · 2023: $1,295 · 2024: $866 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,576.46 | 2019-2025 | |
| Novo Nordisk INC | $1,008.19 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $736.48 | 2019-2024 | Repatha, Otezla, Evenity |
| Pfizer INC. | $643.68 | 2019-2025 | |
| Glaxosmithkline, LLC. | $631.14 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $290.31 | 2020-2024 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.73 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $222.49 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $186.04 | 2021-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $142.08 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $137.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.69 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.81 | 2019-2024 | Xifaxan, Ibschek |
| Ucb, INC. | $125.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $112.14 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.